X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs SANOFI INDIA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB SANOFI INDIA DR. REDDYS LAB/
SANOFI INDIA
 
P/E (TTM) x 31.8 39.5 80.5% View Chart
P/BV x 3.4 8.5 40.0% View Chart
Dividend Yield % 0.8 1.1 73.1%  

Financials

 DR. REDDYS LAB   SANOFI INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
SANOFI INDIA
Dec-16
DR. REDDYS LAB/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2,7884,560 61.1%   
Low Rs1,9024,400 43.2%   
Sales per share (Unadj.) Rs860.81,028.5 83.7%  
Earnings per share (Unadj.) Rs57.1129.0 44.3%  
Cash flow per share (Unadj.) Rs122.0186.0 65.6%  
Dividends per share (Unadj.) Rs20.0068.00 29.4%  
Dividend yield (eoy) %0.91.5 56.2%  
Book value per share (Unadj.) Rs757.7753.6 100.5%  
Shares outstanding (eoy) m165.9123.03 720.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.74.4 62.5%   
Avg P/E ratio x41.134.7 118.3%  
P/CF ratio (eoy) x19.224.1 79.8%  
Price / Book Value ratio x3.15.9 52.1%  
Dividend payout %35.052.7 66.5%   
Avg Mkt Cap Rs m389,034103,174 377.1%   
No. of employees `00023.53.6 649.3%   
Total wages/salary Rs m32,1493,592 895.0%   
Avg. sales/employee Rs Th6,070.86,537.7 92.9%   
Avg. wages/employee Rs Th1,366.6991.4 137.8%   
Avg. net profit/employee Rs Th402.5819.8 49.1%   
INCOME DATA
Net Sales Rs m142,81023,686 602.9%  
Other income Rs m1,552708 219.2%   
Total revenues Rs m144,36224,394 591.8%   
Gross profit Rs m23,5125,281 445.2%  
Depreciation Rs m10,7721,313 820.4%   
Interest Rs m78815 5,253.3%   
Profit before tax Rs m13,5044,661 289.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3801,691 259.0%   
Profit after tax Rs m9,4682,970 318.8%  
Gross profit margin %16.522.3 73.8%  
Effective tax rate %32.436.3 89.4%   
Net profit margin %6.612.5 52.9%  
BALANCE SHEET DATA
Current assets Rs m104,98415,673 669.8%   
Current liabilities Rs m68,9386,678 1,032.3%   
Net working cap to sales %25.238.0 66.5%  
Current ratio x1.52.3 64.9%  
Inventory Days Days7476 97.8%  
Debtors Days Days10422 464.2%  
Net fixed assets Rs m104,3858,098 1,289.0%   
Share capital Rs m830230 360.4%   
"Free" reserves Rs m124,88617,088 730.8%   
Net worth Rs m125,71617,356 724.3%   
Long term debt Rs m25,0890-   
Total assets Rs m225,44325,400 887.6%  
Interest coverage x18.1311.7 5.8%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.60.9 67.9%   
Return on assets %4.511.8 38.7%  
Return on equity %7.517.1 44.0%  
Return on capital %9.726.9 36.0%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m72,6237,145 1,016.4%   
Fx outflow Rs m18,9166,846 276.3%   
Net fx Rs m53,707299 17,962.2%   
CASH FLOW
From Operations Rs m18,0303,226 558.9%  
From Investments Rs m-14,883-1,555 957.1%  
From Financial Activity Rs m-4,440-1,818 244.2%  
Net Cashflow Rs m-1,236-147 840.8%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 5.4 14.4 37.5%  
FIIs % 35.3 14.6 241.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 15,184 499.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   VENUS REMEDIES  SHASUN PHARMA  NOVARTIS  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 18, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS